Ovarian Cancer Treatment Denied by Insurance: How to Appeal

Ovarian cancer has a lower survival rate than most other gynecologic cancers, in part because it is often diagnosed at an advanced stage. The introduction of PARP inhibitors — olaparib (Lynparza), niraparib (Zejula), and rucaparib (Rubraca) — has markedly improved outcomes for patients with BRCA mutations and other homologous recombination deficiencies (HRD). Yet insurance denials for these agents and for essential diagnostic testing remain frequent. If your insurer has denied a PARP inhibitor, BRCA testing, or CA-125 surveillance, you have strong grounds to appeal.

Common Ovarian Cancer Denial Scenarios

PARP Inhibitors: Olaparib and Niraparib

Olaparib (Lynparza) is FDA-approved as maintenance therapy following first-line platinum-based chemotherapy in patients with BRCA-mutated advanced ovarian cancer, and in multiple subsequent-line settings. Niraparib (Zejula) is approved as first-line maintenance for all-comers with advanced ovarian cancer regardless of BRCA status. Rucaparib had approvals that have been withdrawn from the US market.

Insurers deny PARP inhibitors by:

• Requiring BRCA testing documentation before approving olaparib, then separately denying BRCA testing
• Applying narrow interpretation of "BRCA-mutated" — refusing to cover germline-negative but somatic BRCA-mutated patients
• Denying niraparib for patients without BRCA mutations, despite FDA approval for all-comers
• Requiring step therapy through bevacizumab maintenance before approving a PARP inhibitor
• Denying second-line PARP inhibitors for patients who previously received one, even when the second agent targets different mechanisms

BRCA1/2 Germline and Somatic Testing

BRCA1/2 germline testing is covered at no cost-sharing under the ACA for women with a personal or family history meeting USPSTF criteria. However, insurers may deny:

• Germline BRCA testing when the treating oncologist orders it rather than a genetic counselor
• Somatic BRCA testing (tumor-based), which is separately ordered and not covered under the germline ACA mandate
• Hereditary cancer panel testing (broader than BRCA alone), citing cost

Somatic testing — detecting BRCA mutations in the tumor tissue itself — is clinically essential for women whose tumor testing reveals BRCA mutations even when germline testing is negative. Denials of somatic testing are increasingly common and frequently reversible.

HRD Testing (Myriad myChoice, FoundationFocus)

Homologous recombination deficiency (HRD) testing, which assesses genomic instability beyond BRCA, identifies additional patients likely to respond to PARP inhibitors. FDA-approved companion diagnostics exist for some PARP inhibitor labels. Insurers may deny HRD testing as "investigational" even when it is required by the PARP inhibitor's FDA labeling.

CA-125 Tumor Marker Monitoring

CA-125 is the standard biomarker for ovarian cancer monitoring. NCCN guidelines recommend CA-125 testing every 3 months in the first 2 years post-treatment, then less frequently. Insurers sometimes deny CA-125 as "excessive frequency" or as a screening test (subject to different coverage rules) rather than a monitoring test.

Bevacizumab (Avastin)

Bevacizumab is FDA-approved in combination with chemotherapy and as maintenance for advanced ovarian cancer. Insurers may deny it based on:

• Step therapy requirements through chemotherapy-only regimens
• "Investigational" language for maintenance bevacizumab after first-line therapy
• Off-schedule dosing that doesn't match a narrow label interpretation

Your Legal Rights

ACA essential health benefits: Cancer treatment (including oral targeted agents like PARP inhibitors) is a covered EHB. No annual or lifetime caps.

BRCA testing mandate: ACA Section 2713 requires coverage of preventive services with USPSTF A or B ratings at no cost-sharing. BRCA testing for qualifying women carries an A-rating.

External Independent Review: Complete Guide" class="auto-link">External review: Independent review of PARP inhibitor denials has a strong track record of reversal, particularly when the FDA indication is clear and the treating oncologist has documented BRCA/HRD status.

Expedited appeals: Ovarian cancer can progress rapidly. Expedited appeal review — 72 hours — is available when clinical urgency is documented.

Building Your Appeal

1. Pathology report: Confirming ovarian cancer diagnosis, histology (high-grade serous, clear cell, etc.), and stage
2. BRCA/HRD testing results: Germline and/or somatic, with the laboratory report attached
3. Treatment history: Prior platinum-based chemotherapy cycles, response status
4. NCCN Ovarian Cancer Guidelines: Cite specific maintenance therapy recommendations by BRCA status
5. FDA labeling for olaparib or niraparib: Confirming the approved indication matches the patient's clinical situation
6. Letter of medical necessity: From the treating gynecologic oncologist, explaining why the PARP inhibitor is indicated and why alternatives are insufficient

Fight Back With ClaimBack

ClaimBack helps ovarian cancer patients fight insurance denials for PARP inhibitors, genetic testing, and essential monitoring. Our platform makes it easier to build a complete, compelling appeal backed by clinical evidence.

Start your appeal at ClaimBack

A denial is not the final word. Ovarian cancer patients who appeal with complete documentation frequently succeed in reversing their insurer's decision.

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied